BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 25029560)

  • 1. Cutaneous hemophagocytosis after alemtuzumab injection in a patient with Sézary syndrome.
    Jawed SI; Busam K; Wang X; Horwitz S; Querfeld C
    JAMA Dermatol; 2014 Sep; 150(9):1021-3. PubMed ID: 25029560
    [No Abstract]   [Full Text] [Related]  

  • 2. Plaques and tumors in a patient with refractory Sézary syndrome treated with mogamulizumab.
    Ricci C; Pileri A; Agostinelli C; Ambrosi F; Zinzani PL; Sabattini E
    J Dtsch Dermatol Ges; 2018 Oct; 16(10):1263-1265. PubMed ID: 30277017
    [No Abstract]   [Full Text] [Related]  

  • 3. Treatment of Sézary Syndrome With Alemtuzumab: A Series of 5 Cases and a Review of the Literature.
    del Alcázar-Viladomiu E; Tuneu-Valls A; López-Pestaña A; Vidal-Manceñido MJ
    Actas Dermosifiliogr; 2015 Sep; 106(7):e33-9. PubMed ID: 25960287
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pulmonary cryptococcoma in a patient with Sézary syndrome treated with alemtuzumab.
    Hotz C; Ingen-Housz-Oro S; Tran Van Nhieu J; Charlier C; Foulet F; Rahmouni A; Zegai B; Duong TA; Wolkenstein P; Bagot M; Chosidow O
    Eur J Dermatol; 2011; 21(6):1018-20. PubMed ID: 21926045
    [No Abstract]   [Full Text] [Related]  

  • 5. Can the level of CD52 expression on Sézary cells be used to predict the response of Sézary syndrome to alemtuzumab?
    Fernandes IC; Gonçalves M; dos Anjos Teixeira M; Gonçalves C; Coutinho J; Selores M; Alves R; Lima M
    J Am Acad Dermatol; 2012 Nov; 67(5):1083-5. PubMed ID: 23062898
    [No Abstract]   [Full Text] [Related]  

  • 6. Alemtuzumab in refractory Sézary syndrome.
    Reifs CM; Salido-Vallejo R; Garnacho-Saucedo GM; Corte-Sánchez S; González-Menchen A; García-Nieto AV
    An Bras Dermatol; 2016; 91(5):642-644. PubMed ID: 27828640
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hemophagocytic syndrome induced by diaminodiphenylsulfone.
    Hiura Y; Kawabata H; Kanekura T; Terasaki K; Kanzaki T
    J Dermatol; 2007 Oct; 34(10):730-1. PubMed ID: 17908150
    [No Abstract]   [Full Text] [Related]  

  • 8. Alemtuzumab-resistant Sézary syndrome responding to zanolimumab.
    Alexandroff AB; Shpadaruk V; Bamford WM; Kennedy DB; Burd R; Dyer MJ
    Br J Haematol; 2011 Aug; 154(3):419-21. PubMed ID: 21480857
    [No Abstract]   [Full Text] [Related]  

  • 9. Scarring alopecia developing after mogamulizumab-associated rash.
    Raval NS; Snowden CK; De Monnin KS; Yokoyama CC; Choi J; Mehta-Shah N; Rosman IS; Pavlisin J; Musiek AC
    Eur J Dermatol; 2021 Dec; 31(6):841-843. PubMed ID: 35107074
    [No Abstract]   [Full Text] [Related]  

  • 10. Alemtuzumab treatment for Sézary syndrome: A single-center experience.
    Novelli S; García-Muret P; Sierra J; Briones J
    J Dermatolog Treat; 2016; 27(2):179-81. PubMed ID: 26329989
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alemtuzumab in Sézary syndrome: efficient but not innocent.
    Ure UB; Ar MC; Salihoglu A; Guner SI; Baran A; Oguz O; Ferhanoglu B
    Eur J Dermatol; 2007; 17(6):525-9. PubMed ID: 17951134
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Successful treatment of chemotherapy-refractory Sézary syndrome with alemtuzumab (Campath-1H).
    Gautschi O; Blumenthal N; Streit M; Solenthaler M; Hunziker T; Zenhäusern R
    Eur J Haematol; 2004 Jan; 72(1):61-3. PubMed ID: 14962265
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transformation of Sézary syndrome into CD30+ anaplastic large T-cell lymphoma after alemtuzumab therapy with evidence of clonal unity.
    Nevet MJ; Zuckerman T; Sahar D; Bergman R
    Am J Dermatopathol; 2015 Jan; 37(1):73-7. PubMed ID: 25548993
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sézary syndrome associated with granulomatous lesions during treatment with bexarotene.
    Ruiz-de-Casas A; Carrizosa-Esquivel A; Herrera-Saval A; Rios-Martín JJ; Camacho F
    Br J Dermatol; 2006 Feb; 154(2):372-4. PubMed ID: 16433814
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mogamulizumab-induced vitiligo in patients with Sézary syndrome: three cases.
    Algarni AS; Ram-Wolff C; Bagot M; De Masson A
    Eur J Dermatol; 2021 Apr; 31(2):213-216. PubMed ID: 33814357
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sezary syndrome presenting with leonine facies and treated with low-dose subcutaneous alemtuzumab.
    Oliveira A; Lobo I; Alves R; Lima M; Selores M
    Dermatol Online J; 2011 Nov; 17(11):6. PubMed ID: 22136862
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alemtuzumab treatment for hemophagocytic lymphohistiocytosis.
    Machaczka M; Vaktnäs J; Chiang SC; Bryceson YT
    Nat Rev Clin Oncol; 2010 Oct; 7(10):. PubMed ID: 21080519
    [No Abstract]   [Full Text] [Related]  

  • 18. Mogamulizumab-induced toxicoderma-like eruptions and autoimmune hepatitis successfully treated with azathioprine in adult T-cell leukaemia/lymphoma.
    Nishizawa A; Ishikawa T; Hirose M; Satoh H; Nishii S; Tomita K; Hokari R; Satoh T
    Eur J Dermatol; 2017 Dec; 27(6):651-652. PubMed ID: 28739547
    [No Abstract]   [Full Text] [Related]  

  • 19. Multiple abscesses in a patient treated with cetuximab.
    Ricci F; Guerriero C; Paradisi A; Fossati B; Miccichè F; Valentini V; Capizzi R
    Eur J Dermatol; 2013; 23(1):103-4. PubMed ID: 23238287
    [No Abstract]   [Full Text] [Related]  

  • 20. Association of autoimmunity and long-term complete remission in patients with Sézary syndrome treated with mogamulizumab.
    Bonnet P; Battistella M; Roelens M; Ram-Wolff C; Herms F; Frumholtz L; Bouaziz JD; Brice P; Moins-Teisserenc H; Bagot M; de Masson A
    Br J Dermatol; 2019 Feb; 180(2):419-420. PubMed ID: 30328116
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.